Camelot Portfolios LLC Purchases Shares of 1,492 Eli Lilly and Company (NYSE:LLY)

Camelot Portfolios LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,492 shares of the company’s stock, valued at approximately $870,000.

Several other hedge funds have also added to or reduced their stakes in LLY. Norges Bank acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $3,416,206,000. Moneta Group Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares during the last quarter. Morgan Stanley increased its position in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Imprint Wealth LLC increased its position in Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after buying an additional 1,747,946 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter worth $445,944,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.6 %

Shares of LLY stock traded up $12.35 during mid-day trading on Wednesday, reaching $776.31. 3,041,599 shares of the stock traded hands, compared to its average volume of 3,218,342. The stock’s fifty day simple moving average is $742.32 and its two-hundred day simple moving average is $642.33. Eli Lilly and Company has a 1-year low of $351.27 and a 1-year high of $800.78. The company has a market cap of $737.62 billion, a price-to-earnings ratio of 134.10, a price-to-earnings-growth ratio of 1.67 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm posted $2.09 earnings per share. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on LLY shares. Barclays increased their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Truist Financial restated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $700.00.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total value of $21,821,453.78. Following the transaction, the insider now directly owns 99,719,884 shares of the company’s stock, valued at $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 195,055 shares of company stock valued at $125,254,657 over the last ninety days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.